MacAnxiety Research Centre

Compulsive Personality Disorder

Obsessive-Compulsive Disorder

Social Phobia

Agoraphobia

Anxiety Disorders

Panic Disorder

Depressive Disorder

Phobic Disorders

Depression

Major Depressive Disorder

Serotonin

Topiramate

Pregabalin

RO4917838

Lyrica

Psilocybin

SSRIs

Sertraline

Methylphenidate Hydrochloride

Bitopertin

McMaster University

Hamilton Health Sciences (HHS)

Roche

atai Therapeutics, Inc.

condition

Treatment-Resistant Depressive Disorder

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatment resistant Major Depressive disorder (TRD) and will characterize the onset and durability of antidepressant effects of VLS-01-BU versus placebo.

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

MacAnxiety Research Centre | MacAnxiety Research Centre

Site insights

Active trials

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

Trial sponsors